

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT****Complete if Known**

Application No.	10/612,179
Filing Date	July 2, 2003
First Named Inventor	Roland Kreutzer
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	26421-15777

Sheet

1

of

3

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document No. Number – Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	A1	US-5,789,230	08-04-1998	Cotton et al.
	A2	US-5,328,470	07-12-1994	Nabel et al.
	A3	US-2008/0166800	07-10-2008	Kreutzer et al.
	A4	US-2008/0171862	07-17-2008	Kreutzer et al.
	A5	US-2008/0182981	07-31-2008	Kreutzer et al.
	A6	US-2008/0233651	09-25-2008	Kreutzer et al.
	A7	US-2008/0261303	10-23-2008	Kreutzer et al.

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> – Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
	B1	GB 9927444.1 (Corresponding to WO 01/36646 A1)	11-19-1999	Zernika- Goetz et al.	
	B2	WO 1996/017057	06-06-1996	The University of Queensland	
	B3	WO 1997/043431	11-20-1997	BERTLING	
	B4	EP 1214945 A2 (With English Abstract)	01-29-2000	Kreutzer et al.	
	B5	EP 1550719 A1 (With English Abstract)	07-06-2005	ALNYLAM EUROP AG	
	B6	EP 1550719 B1 (With English Abstract)	12-24-2008	ALNYLAM EUROP AG	
	B7	DE 20023125 U1 (With English Abstract; Related to WO200044895)	01-29-2000	Ribopharma AG	
	B8	DE 10230997 A1 (With English Abstract; Related to	07-09-2002	Ribopharma AG	

Examiner  
SignatureDate  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Applicant's unique citation designation number (optional). 2See Kinds Codes of USPTO Patent Documents at [www.uspto.gov/mpep/201502](http://www.uspto.gov/mpep/201502). 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Complete if Known</b>	
				Application No.	10/612,179
				Filing Date	July 2, 2003
				First Named Inventor	Roland Kreutzer
				Art Unit	1635
				Examiner Name	Kimberly Chong
Sheet	2	of	3	Attorney Docket Number	26421-15777

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> – Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
		WO03035870)			
	B9	DE 10230996 AI (With English Abstract; Related to WO03035870)	07-09-2002	Ribopharma AG	
	B10	DE 10163098 AI (With English Abstract; Related to WO03035870)	12-20-2001	Ribopharma AG	
	B11	DE 10100588 AI (With English Abstract)	01-09-2001	Ribopharma AG	

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T <sup>6</sup>
	C1	Notice of Opposition to European Patent Application No. EP 05002454.6, filed by SIRNA Therapeutics, filed on September 21, 2009, 42 Pages.		
	C2	Decision to revoke European Patent EP 1144623 of Alnylam Europe AG, December 19, 2008, 50 Pages.		X
	C3	Decision to revoke European Patent EP 1214945 of Alnylam Europe AG, January 20, 2009, 56 Pages.		X
	C4	Decision to revoke European Patent EP 10080167 of Alnylam Europe AG, March 18, 2009, 26 Pages.		X
	C5	Office Action for U.S. Patent Application No. 10/383,099, December 17, 2009, 9 Pages.		
	C6	Office Action for U.S. Patent Application No. 10/382,395 October 5, 2009, 9 Pages.		
	C7	Office Action for U.S. Patent Application No. 10/612,179 December 17, 2009, 9 Pages.		
	C8	Notice of Reasons for Rejection for Japan Patent Application No. 2009-002824, June 16, 2009, 15 Pages.		X
	C9	Notice of Reasons for Rejection for Japan Patent Application No. 2009-002826, June 16, 2009, 15 Pages.		X
	C10	Decision of Rejection for Japan Patent Application No. 2009-002824, March 9, 2010, 4 Pages.		X
	C11	Decision of Rejection for Japan Patent Application No. 2009-002826, March 9, 2010, 4 Pages.		X
	C12	JIANG, A., et al., "In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies," Gene Therapy, 1999, Pages 1982-1987, Vol. 6.		
	C13	LUBBERTS, E., et al., "Adenoviral Vector-Mediated Overexpression of IL-4 in the Knee Joint of Mice with Collagen-Induced Arthritis Prevents Cartilage Destruction," The Journal of Immunology, 1999, Pages 4546-4556.		
	C14	NISHI, T., et al., "High-Efficiency in Vivo Gene Transfer Using Intraarterial Plasmid DNA Injection following in		
Examiner Signature		Date Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Applicant's unique citation designation number (optional). 2See Kinds Codes of USPTO Patent Documents at [www.uspto.gov/mpep/201502.1](http://www.uspto.gov/mpep/201502.1). 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT****Complete if Known**

Application No.	10/612,179
Filing Date	July 2, 2003
First Named Inventor	Roland Kreutzer
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	26421-15777

Sheet

3

of

3

**OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
		Vivo Electroporation <sup>1</sup> , Cancer Research, March 1, 1996, Pages 1050-1055, Vol. 56.	
	C15	NIU, G., et al., "Gene Therapy with Dominant-negative Stat3 Suppresses Growth of the Murine Melanoma B16 Tumor in Vivo <sup>1</sup> ," Cancer Research, October 15, 1999, Pages 5059-5063, Vol. 59.	
	C16	XIE, Y., et al., "Efficacy of Adenovirus-mediated CD/5-FC and HSV-I Thymidine Kinase/Ganciclovir Suicide Gene Therapies Concomitant with p53 Gene Therapy <sup>1</sup> ," Clinical Cancer Research, December 1999, Pages 4224-4232, Vol. 5.	
	C17	Auszug aus der online-Rolle des EPA, Excerpt from the European Patent Register for EP 1147204, Database last updated on June 18, 2008, 4 Pages.	X
	C18	Pschyrembel Klinisches Wörterbuch, 259., neu bearbeitete Auflage, Pschyrembel Clinical Dictionary 259 <sup>th</sup> , Revised Edition, 2002, 1 page, with English summary.	X

Examiner  
SignatureDate  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Applicant's unique citation designation number (optional). 2See Kinds Codes of USPTO Patent Documents at [www.uspto.gov/MPEP/201602.1](http://www.uspto.gov/MPEP/201602.1)  
3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.